摘要
肝纤维化由慢性肝炎造成,若治疗不及时将发展成为肝硬化、肝癌。目前,临床上尚无理想的治疗药物。随着肝纤维化分子机制逐渐得以阐明、基因技术不断发展,使肝纤维化的治疗成为可能。目前,肝纤维化治疗主要是通过抑制肝星状细胞(HSC)活化、增殖,抑制细胞外基质(ECM)的合成,促进ECM的降解,诱导活化HSC凋亡。本文就肝纤维化的分子机制和治疗进行综述,为以后的研究提供参考。
Chronic hepatitis leads to hepatic fibrosis which can further develop into cirrhosis and liver cancer without timely treatment.At present,there is no ideal therapeutic drug in the clinical practice.As the molecular mechanism of liver fibrosis gradually clarifies and the gene technology develops,it is possible to treat liver fibrosis.At present,the therapy of hepatic fibrosis mainly inhibits the activation and proliferation of HSC,inhibits the synthesis of ECM,promotes the degradation of ECM and induces the apoptosis of activation of HSC.In order to provide a reference for future researches,this article has reviewed several aspects of the molecular mechanism and therapies.
出处
《中国医院药学杂志》
CAS
北大核心
2017年第18期1873-1876,1881,共5页
Chinese Journal of Hospital Pharmacy
